David Altshuler, M.D., Ph.D. Deputy Director and Chief Academic Officer, Broad Institute of Harvard and MIT Cambridge, Massachusetts, U.S.

Transcription

1 David Altshuler, M.D., Ph.D. Deputy Director and Chief Academic Officer, Broad Institute of Harvard and MIT Cambridge, Massachusetts, U.S. Endocrinologist and human geneticist David Altshuler is a professor of genetics and of medicine at Harvard Medical School, in the department of Molecular Biology, the Center for Human Genetic Research, and the Diabetes Unit at Massachusetts General Hospital, and Adjunct Professor of Biology at MIT. David is one of four founding members of the Broad Institute of Harvard and MIT and serves as the Institute s first Deputy Director and Chief Academic Officer. He is also Director of Broad s Program in Medical and Population Genetics. David studies human genetic variation and its application to disease, using tools and information from the Human Genome Project. He has been a lead investigator in The SNP Consortium, the International HapMap Project, and the 1,000 Genomes Project public private partnerships that have created public maps of human genome sequence variation as a foundation for disease research. His work has contributed to the identification of gene variants that are associated with the risk of common conditions, including type 2 diabetes, blood cholesterol and myocardial infarction, as well as prostate cancer, systemic lupus erythematosis, and rheumatoid arthritis. He is a member of the US Institute of Medicine, the American Society for Clinical Investigation, the Association of American Physicians, and of the Board of Directors of the American Society of Human Genetics and of Vertex Pharmaceuticals. David was awarded the Curt Stern Award of the American Society of Human Genetics and the Outstanding Scientific Achievement Award of the American Diabetes Association.

2 David Haussler, Ph.D. Investigator, Howard Hughes Medical Institute Distinguished Professor, Biomolecular Engineering, University of California, Santa Cruz Scientific Co Director, California Institute for Quantitative Biosciences (QB3) Cofounder, Genome 10K Project Director, Center for Biomolecular Science & Engineering Director, UCSC Cancer Genomics Hub David Haussler develops new statistical and algorithmic methods to explore the molecular function, evolution, and disease process in the human genome, integrating comparative and high throughput genomics data to study gene structure, function, and regulation. He is credited with pioneering the use in genomics of hidden Markov models (HMMs), stochastic context free grammars, and discriminative kernel methods, the latter first applied to gene expression in cancer in As a collaborator on the international Human Genome Project, his team posted the first publicly available computational assembly of the human genome sequence on the Internet on July 7, His team subsequently developed the UCSC Genome Browser, a web based tool that is used extensively in biomedical research and serves, along with the Ensembl platform, virtually all large scale vertebrate genomics projects, including NHGRI s ENCODE project, the 1000 Genomes Project, and NCI s TCGA. He built the CGHub database to hold NCI s cancer genome data. His group s informatics work on cancer genomics provides a complete analysis pipeline from raw DNA reads through the detection and interpretation of mutations and altered gene expression in tumor samples. He collaborates with the Stand Up To Cancer Dream Teams and TCGA to discover molecular causes of cancer and pioneer a new personalized, genomics based approach to cancer treatment. Haussler received his Ph.D. in computer science from the University of Colorado at Boulder. He is a member of the National Academy of Sciences and the American Academy of Arts and Sciences and a fellow of AAAS and AAAI. He has won a number of awards, including the 2011 Weldon Memorial prize for application of mathematics and statistics to biology, 2009 ASHG Curt Stern Award in Human Genetics, the 2008 Senior Scientist Accomplishment Award from the International Society for Computational Biology, the 2006 Dickson Prize for Science from Carnegie Mellon University, and the 2003 ACM/AAAI Allen Newell Award in Artificial Intelligence.

3 Thomas J. Hudson, M.D. President and Scientific Director, Ontario Institute for Cancer Research Toronto, Ontario, CA Dr. Thomas J. Hudson is President and Scientific Director of the Ontario Institute for Cancer Research (OICR), an Institute created to support multidisciplinary teams needed to effectively translate research discoveries into interventions for better prevention, detection, diagnosis and treatment of cancer. Since its inception, OICR has launched several large scale programs including the Ontario Health Study, the One Millimetre Cancer Challenge, the Cancer Stem Cell Program, the Pancreatic Cancer Genome Project (which is part of the International Cancer Genome Consortium), the Terry Fox Research Institute/OICR Selective Therapies Program and High Impact Clinical Trials. Dr. Hudson is internationally renowned for his work in genomics and human genome variation. Past positions include leadership roles as Director of the McGill University and Genome Quebec Innovation Centre and Assistant Director of the Whitehead/MIT Center for Genome Research, where he led a team that generated physical and gene maps of the human and mouse genomes. Dr. Hudson has been a founding member of the International Haplotype Map Consortium, the Public Population Project in Genomics (P3G) and the International Cancer Genome Consortium. His laboratory at OICR is involved in the study of genome variation that affects cancer predisposition, progression, and response to therapy. His main project focuses on the genetic architecture of loci associated with risk to colorectal cancer. In 2007, Dr. Hudson was appointed to the rank of Professor in the Department of Molecular Genetics at the University of Toronto. Dr. Hudson is a fellow of the Royal Society of Canada. He is editor in chief of the journal Human Genetics. Dr. Hudson has co authored over 250 peer reviewed scientific publications.

4 Brad Margus Co founder and volunteer president of the A T Children's Project Coconut Creek, Florida, U.S. Brad Margus is co founder and volunteer president of the A T Children's Project, which raises funds for and promotes research aimed at finding a treatment for the lethal childhood genetic neurodegenerative disease known as ataxia telangiectasia. Two of his sons have this disease. He co founded and was CEO of Envoy Therapeutics (sold to Takeda Pharmaceuticals in 2012). Prior to starting Envoy Therapeutics, Margus started Perlegen Sciences as CEO and became Vice Chairman in Before his role at Perlegen, he was CEO at an international food company for 14 years. While still running his food business, Margus studied molecular genetics, formed a non profit, raised over $30 million through over 140,000 donations, organized dozens of scientific conferences, funded research projects worldwide, created tissue banks and gene expression profile databases, established a clinic at Johns Hopkins Hospital, and coordinated clinical trials. He also advocated for other genetic disorders, frequently testifying before Congress and appearing in the national media. He serves as Global Business Advisor, Harvard Business School; Board of Directors, Children s Neurobiological Solutions; and advisor to the Rare Disease Network. He has an MBA from Harvard University.

5 Elizabeth G. Nabel, M.D. President, Brigham and Women s Health Care Boston, Massachusetts, U.S. Elizabeth G. Nabel, M.D. is President of Brigham and Women's Health Care, comprised of Brigham and Women s Hospital and Brigham and Women s Faulkner Hospital. Dr. Nabel is a board certified cardiologist and previously served as the Director of the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health. Prior to her appointment as Director, she was the Institute's Scientific Director of Clinical Research. She previously held the title of Chief, Division of Cardiology, Director, Cardiovascular Research Center, and Professor of Internal Medicine and Physiology at the University of Michigan. Dr. Nabel is internationally recognized for her research in the molecular genetics of cardiovascular disease, and has received numerous awards including but not limited to, the Distinguished Achievement Award from the Basic Cardiovascular Sciences Council of the American Heart Association and the Amgen Scientific Achievement Award from the American Society for Biochemistry and Molecular Biology. An internationally recognized scholar, Dr. Nabel has received five honorary doctoral degrees, including the University of Leuven, Leuven, Belgium. Dr. Nabel was elected to the Institute of Medicine of the National Academy of Sciences and was elected to serve on the IOM Council. She received her medical education at Cornell University Medical College.

6 Charles L. Sawyers, M.D. Chair, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center New York City, New York, U.S. Charles Sawyers is an Investigator of the Howard Hughes Medical Institute and the Chairman of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center. His studies of BCR ABL tyrosine kinase function in chronic myeloid leukemia, in collaboration with Brian Druker and Novartis, led to the development of the kinase inhibitor imatinib as primary therapy for CML. This was followed by his discovery that BCR ABL mutations confer imatinib resistance, and development of the second generation ABL kinase inhibitor dasatinib, in collaboration with Bristol Myers Squibb. Sawyers' work in prostate cancer defined upregulation of androgen receptor signaling as the primary mechanism of resistance to hormone therapy, resulting in the discovery of the antiandrogen MDV3100 in collaboration with Michael Jung, that prolongs survival in men with metastatic prostate cancer. Sawyers is President elect of the American Association for Cancer Research and the past President of the American Society of Clinical Investigation and served on the National Cancer Institute s Board of Scientific Councilors. He is a member of the National Academy of Sciences and the Institute of Medicine and co recipient of the 2009 Lasker~DeBakey Clinical Medical Research Award, and most recently has been appointed by President Obama to the National Cancer Advisory Board.

7 Michael R Stratton Director of Wellcome Trust Sanger Institute Hinxton UK Mike Stratton studied medicine at Oxford University and Guy s Hospital, specialised in histopathology and obtained his PhD at the Institute of Cancer Research, London. His research is in cancer genetics. Early studies focused on inherited predisposition, notably discovery of the breast cancer susceptibility gene BRCA2. Subsequently, he initiated genome wide sequencing for somatic mutations in cancer, discovering BRAF mutations in malignant melanoma and describing basic mutational patterns in cancer genomes. He is Director of the Wellcome Trust Sanger Institute, Hinxton, UK.